HuaDao Bio Advances Toward STAR Market Listing with D+2 Financing to Enhance CAR-T Therapy Accessibility
Huadao Biopharma
Developer and Manufacturer of Cell-Based Immunotherapy Drugs
▲November 6-7The 10th Guangzhou (Greater Bay Area) BiomedicalInnovators SummitScan to register
Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any issues are welcome. This article is only an introduction to pharmaceuticals related to healthcare and is not a recommendation of treatment plans (if involved). This article does not constitute any investment advice.
PharmaCircleMonitoring Shows: Recently, HuaDao CAR-Tcell (Shanghai) Biomedical Co., Ltd. (hereinafter referred to as "HuaDao Biomedical") successfully completed a D+2 round of financing exceeding 100 million yuan. This round of financing was led by Bo'ai New Open Source (300109.sz), with participation from Jinghu Capital, Wuhan He'er, Zhejiang Shenchang, Ningbo Zibei, and other institutions and investors. The funds will mainly be used to accelerate the research, development, and industrialization process of affordable cell drugs, further promoting the construction of HuaDao Biomedical's first intelligent manufacturing industrialization base for CAR-T cell drugs in Shanghai.Commercial Production Application Landing, to support the safety of China's biopharmaceutical industry chain and supply chain, achieving CAR-T cell drugs'Pricing Autonomy`, providing affordable and accessible CAR-T cell drugs for the general public.`
Yu Xuejun, Chairman and General Manager of HuaDao CAR-Tcell, stated: The biopharmaceutical industry is a strategic emerging industry related to the national economy, people's livelihood, and national security. Cell immunotherapy represented by Chimeric Antigen Receptor T-cell (CAR-T) has led cancer treatment into a new era (the third revolution in the history of cancer treatment). The research and development and industrialization of CAR-T cell drugs are led by China and the United States (each having seven approved drugs on the market), but the million-yuan price level clearly exceeds the out-of-pocket payment ability of Chinese patients and the coverage range of medical insurance reimbursement. Therefore, overcoming key bottleneck technologies, reducing the cost of cell product preparation and management operations, and making cell drugs accessible and affordable is a critical industrial technology bottleneck and commercialization challenge that Chinese CAR-T cell drug companies must address. We sincerely thank all partners for their trust in HuaDao CAR-Tcell’s persistent efforts toward an accessible cell drug platform technology. Let us look forward to the unmanned intelligent production management system to be showcased in the first phase of the intelligent manufacturing industrialization base (Shanghai) construction project for HuaDao CAR-Tcell’s CAR-T cell drugs, which will revolutionarily disrupt the manufacturing costs of personalized CAR-T cell drugs and fulfill the historical mission of innovation-driven development in the biopharmaceutical industry to achieve people’s health and happiness. We also sincerely invite more partners to follow the company’s subsequent pre-IPO financing round and participate in promoting "China-made alternatives, accessibility, and affordability."HuaDao CAR-Tcell Bravely Ventures into the STAR Market, jointly build a universal cell drug industry with Chinese characteristics that benefits people around the world.
Reference:
NMPA/CDE；
Moxie Pharma Database, https://pharma.bcpmdata.com/;
FDA/EMA/PMDA；
Relevant companies' public disclosures (unless otherwise noted, images in the main text are from the companies' official websites);
Etc.
Rooted in Shanghai and radiating globally, PharmaCircle serves as a strategic platform for the biopharmaceuticals industry. With the mission of "enabling the borderless flow of intelligence and networks," it has built a comprehensive empowerment system covering the entire pharmaceutical industrial chain, including R&D, production, distribution, and commercialization. Through four core engines—intelligent cloud services, precise resource linking, an industry think tank, and ecological communities—it aims to create infrastructure for the fluid exchange of value within China's pharmaceutical sector.
Under the dual waves of globalization and digitalization, PharmaCircle is redefining the circulation paradigm of pharmaceutical resources — it is not only a hub for information and networking but also a catalyst for industrial transformation. With China as the origin, we weave a global network of pharmaceutical intelligence, making every precise connection a catalyst for enterprises' leapfrog growth.
